bih.button.backtotop.text
HomeLab Services GuideTests
BROWSE BY TEST NAME
#
%
1
2
3
5
8
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Z
Clear
Overview
ข้อมูลทั่วไป Specimen
ข้อมูลสิ่งส่งตรวจ Performance
ข้อมูลการทดสอบ Clinical & Interpretation
ข้อมูลทางคลินิก
 
Test Code (รหัสการทดสอบ):
LAB64
Order Name (ชื่อการทดสอบ):
Package GenomeHealth-Premium
 
Specimen / Container (สิ่งส่งตรวจ/ภาชนะ):
EDTA 3 mL (2 tube)  - Lavender tube

Document required:
Consent for Genomic Medicine Testing (PGM-00102)
 
Turnaround Time (ระยะเวลารอผล):
Reported within 6-8 weeks for WGS screening report
Reported within 4 weeks for Wellness Prime (SNP and PICK) **
 
Useful For (ประโยชน์การทดสอบ):
•Individuals who have a family or personal history of certain cancer, cardio,  malignant Hyeprthermia and other conditions.
•Healthy people who are interested to know about the risk of your body’s predisposition for developing certain cancer, cardio,  malignant Hyeprthermia and other conditions. 
•Individuals who are interested to know about your genetic predispositions to certain health conditions. This information can help you make informed lifestyle choices to proactively manage your health.
 
Methodology (วิธีการทดสอบ):
1.Whole Genome Sequencing (WGS)
2.Microarray 20 million SNP/InDels
 
Test List In Profile (การทดสอบใน Profile):
WGS screening report
1. Cancer screen report 
2. Cardio screen report 
3. Additional finding report
4. Malignant Hyeprthermia report (CACNA1S, RYR1)

Wellness Prime (SNP and PICK) **
1. Sport Genes
2. Nutrient Metabolism
3. Psychological Traits
4. Life Guidance
5. Exposure risk
 
AliasesName (ชื่อเรียกอื่นๆ) :
Whole genome sequencing, 
WGS, wellness, cancer, cardio, additional, MH
 
 
 
Test Code (รหัสการทดสอบ):
LAB64
Order Name (ชื่อการทดสอบ):
Package GenomeHealth-Premium
 
Collection Specimen Or Container (สิ่งส่งตรวจ/ภาชนะ):
EDTA 3 mL (2 tube)  - Lavender tube

Document required:
Consent for Genomic Medicine Testing (PGM-00102)
 
Rejection Criteria (เกณฑ์ปฏิเสธสิ่งส่งตรวจ):
Use heparin as anticoagulant,
Severe clotted specimen
 
Specimen Stabillity (ความคงตัวของสิ่งส่งตรวจ):
EDTA: Refrigerated 2°C to 8°C for 7 days 
 
 
 
Test Code (รหัสการทดสอบ):
LAB64
Order Name (ชื่อการทดสอบ):
Package GenomeHealth-Premium
 
Turnaround Time (ระยะเวลารอผล):
Reported within 6-8 weeks for WGS screening report
Reported within 4 weeks for Wellness Prime (SNP and PICK) **
 
Performing Location (หน่วยงานที่ทำการทดสอบ):
Clinical Genomics Tel. 14252
 
 
 
Test Code (รหัสการทดสอบ):
LAB64
Order Name (ชื่อการทดสอบ):
Package GenomeHealth-Premium
 
 
Clinical Information (ข้อมูลทางคลินิก):
Package GenomeHealth-Premium
This comprehensive package offers a wide range of genetic screenings, including:
•    Cancer Screening: Analysis of over 90 genes associated with various inherited cancers, such as Breast, Ovarian, Colorectal, Melanoma, Gastric, Pancreatic, Prostate, Renal, Parathyroid, Pituitary adenoma, Neuroblastoma, leukemia, and other familial cancer syndromes.
•    Cardiovascular Screening: Evaluation of over 95 genes related to heart conditions, including Aortopathies, Arrhythmias, Cardiomyopathies, Thrombophilia, Neuromuscular conditions, Hypercholesterolemia, congenital heart disease, Pulmonary hypertension, and other heart syndromes.
•    Additional Findings: Evaluation of over 14 genes related to various conditions such as Wilson disease, Biotinidase deficiency, Pompe disease, hereditary hemochromatosis, Alpha-1-antitrypsin deficiency.
•    Malignant Hyperthermia Screening: Analysis of genes (CACNA1S and RYR1) associated with an increased risk of malignant hyperthermia, a potentially life-threatening reaction to certain anesthetics.
•    Wellness Prime (SNP and PICK): Includes over 100 detailed reports across 5 key categories, providing insights into sports performance, nutrient metabolism, psychological traits, lifestyle guidance, and environmental risk factors.
 
Clinical Reference (เอกสารอ้างอิง):
1. https://www.omim.org (Retrieved 1 July 2022)
2.https://www.cancer.gov/publications/dictionaries/cancer-terms/def/inherited-cancer-syndrome ((Retrieved 1 July 2022)
3. Cirino AL, Harris S, Lakdawala NK, et al. Role of Genetic Testing in Inherited Cardiovascular Disease: A Review. JAMA Cardiol. 2017;2(10):1153–1160. doi:10.1001/jamacardio.2017.2352
4. Gonsalves, Stephen G., et al. "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR 1 or CACNA 1S genotypes." Clinical Pharmacology & Therapeutics 105.6 (2019): 1338-1344.
5. www.bangkokgenomics.com (Retrieved: 19 Oct 2024)